Valneva Shares: Analysts See Substantial Upside Potential
21.11.2025 - 11:42:04 | boerse-global.de
Despite recent market jitters affecting investor sentiment, the underlying financial performance of French vaccine specialist Valneva tells a different story. While the company’s share price has experienced a significant downturn, its recently released nine-month results for 2025 were robust, with management reaffirming its full-year outlook even amidst a challenging operating climate. Adding a jolt of optimism to this gloomy market atmosphere, a prominent analyst firm has issued a striking assessment, suggesting the stock’s potential could far exceed its current trading level.
The perspective from investment bank Stifel provides a compelling counter-narrative to the current share price weakness. The firm has reiterated its “Buy” recommendation, attaching a price target of Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos.
